AbbVie Etentamig BCMA x CD3 Bispecific Meets Dual Primary Endpoints in Phase 3 CERVINO in Relapsed/Refractory Multiple Myeloma; 74% ORR, 60% Risk Reduction
AbbVie (NYSE: ABBV) announced Thursday September 3, 2026 positive topline results from the Phase 3 CERVINO trial of etentamig (an investigational monthly-dosed BCMA x CD3 bispecific T-cell engager) versus investigator's choice of standard available therapies in patients with triple-class-exposed relapsed/refractory multiple myeloma. The 393-patient trial met both dual primary endpoints: 74% objective response rate versus standard therapies plus a 60% reduction in the risk of disease progression or death (hazard ratio 0.40). Median follow-up was 11.4 months; safety was manageable with cytokine release syndrome and infection rates consistent with the BCMA bispecific class. Full CERVINO data will be presented in a plenary session at the 23rd International Myeloma Society Annual Meeting September 23-26, 2026 in Glasgow, Scotland. Etentamig would enter a competitive BCMA bispecific field led by Johnson & Johnson's Tecvayli (teclistamab) and Elrexfio (elranatamab, Pfizer), with the monthly dosing profile positioned as convenience-differentiated versus the weekly and biweekly regimens of the incumbents.